Related Experiment Video

Updated: Jun 25, 2026

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
07:57

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

Heat shock protein inhibitors and vaccines as new agents in cancer treatment

Eleni M Karapanagiotou1, Kostas Syrigos, Muhammad Wasif Saif

  • 1Athens Medical School, Medical Oncology, Athens, Greece.

Expert Opinion on Investigational Drugs
|February 25, 2009
PubMed
Abstract

Insights

Heat shock protein (HSP) inhibitors show promise as novel anticancer treatments, while HSP vaccines are already established in cancer therapy. Further clinical trials are needed for HSP90 inhibitors to confirm their efficacy.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Heat shock proteins (HSP) are crucial molecular chaperones in human cells.
  • HSP are implicated in tumor progression, including proliferation, invasion, angiogenesis, metastasis, and cell death.
  • HSP can stimulate anti-tumor immune responses by presenting tumor antigens.

Purpose of the Study:

  • To review the efficacy of Heat shock protein 90 (HSP90) inhibitors as anticancer agents.
  • To evaluate the benefits of autologous HSP vaccines in cancer treatment, including adjuvant and first-line settings.

Main Methods:

  • Reviewed current evidence on HSP90 inhibitors, including geldanamycin analogues and novel synthetic molecules.
  • Assessed the use of tumor-derived HSP for cancer immunotherapy.

Main Results:

  • HSP90 inhibitors demonstrate potential as a therapeutic strategy against cancer.
  • HSP vaccination has a recognized role in cancer treatment protocols.

Conclusions:

  • HSP90 inhibitors offer a promising avenue for anticancer therapy, warranting further large-scale clinical trials.
  • HSP vaccination is an established and valuable component of cancer treatment.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...